These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 21192147)

  • 21. Improved symptom control, functioning and satisfaction in French patients treated with long-acting injectable risperidone.
    Llorca PM; Bouhours P; Moreau-Mallet V;
    Encephale; 2008 Apr; 34(2):170-8. PubMed ID: 18597725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness.
    Lasser RA; Bossie CA; Zhu Y; Locklear JC; Kane JM
    Ann Clin Psychiatry; 2007; 19(2):65-71. PubMed ID: 17612845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonresponse to clozapine and premorbid functioning in treatment of refractory schizophrenia.
    Kelly DL; Feldman S; Boggs DL; Gale E; Conley RR
    Compr Psychiatry; 2010; 51(3):298-302. PubMed ID: 20399340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient-based and clinician-based support for the remission criteria in schizophrenia.
    Docherty JP; Bossie CA; Lachaux B; Bouhours P; Zhu Y; Lasser R; Gharabawi GM
    Int Clin Psychopharmacol; 2007 Jan; 22(1):51-5. PubMed ID: 17159460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable.
    Gharabawi G; Bossie C; Turkoz I; Kujawa M; Mahmoud R; Simpson G
    J Nerv Ment Dis; 2007 Dec; 195(12):976-82. PubMed ID: 18091190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries.
    Peuskens J; Olivares JM; Pecenak J; Tuma I; Bij de Weg H; Eriksson L; Resseler S; Akhras K; Jacobs A
    Curr Med Res Opin; 2010 Mar; 26(3):501-9. PubMed ID: 20014981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical outcomes of long-acting risperidone in recent versus long-term diagnosed Belgian schizophrenic patients: results from electronic Schizophrenia Treatment Adherence Registry (e-STAR) and Trial for the Initiation and Maintenance Of REmission in Schizophrenia with risperidone (TIMORES).
    Dubois V; Peuskens J; Geerts P; Detraux J
    Early Interv Psychiatry; 2014 Feb; 8(1):39-49. PubMed ID: 23343330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical experience with the long-acting injectable formulation of the atypical antipsychotic, risperidone.
    Martin SD; Libretto SE; Pratt DJ; Brewin JS; Huq ZU; Saleh BT
    Curr Med Res Opin; 2003; 19(4):298-305. PubMed ID: 12841922
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Premorbid adjustment in schizophrenia and schizoaffective disorder.
    Saracco-Alvarez R; Rodríguez-Verdugo S; García-Anaya M; Fresán A
    Psychiatry Res; 2009 Feb; 165(3):234-40. PubMed ID: 19162333
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Direct transition to long-acting risperidone--analysis of long-term efficacy.
    Kissling W; Heres S; Lloyd K; Sacchetti E; Bouhours P; Medori R; Llorca PM
    J Psychopharmacol; 2005 Sep; 19(5 Suppl):15-21. PubMed ID: 16144782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Relationships between insight and medication adherence in subjects with psychosis].
    Droulout T; Liraud F; Verdoux H
    Encephale; 2003; 29(5):430-7. PubMed ID: 14615692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatment.
    Lambert M; De Marinis T; Pfeil J; Naber D; Schreiner A
    Eur Psychiatry; 2010 May; 25(4):220-9. PubMed ID: 19926263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
    Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety.
    Hawley C; Turner M; Latif MA; Curtis V; Saleem PT; Wilton K
    Hum Psychopharmacol; 2010 Jan; 25(1):37-46. PubMed ID: 20041474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder.
    Lasser R; Bossie CA; Gharabawi G; Eerdekens M; Nasrallah HA
    J Affect Disord; 2004 Dec; 83(2-3):263-75. PubMed ID: 15555724
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlates, change and 'state or trait' properties of insight in schizophrenia.
    Wiffen BD; Rabinowitz J; Lex A; David AS
    Schizophr Res; 2010 Sep; 122(1-3):94-103. PubMed ID: 20382507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risperidone long-acting therapy in stable patients with recently diagnosed schizophrenia.
    Macfadden W; Bossie CA; Turkoz I; Haskins JT
    Int Clin Psychopharmacol; 2010 Mar; 25(2):75-82. PubMed ID: 20101185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does oral antipsychotic pre-treatment influence outcome of a switch to long-acting injectable risperidone in patients with schizophrenia?
    Schmauss M; Diekamp B; Gerwe M; Schreiner A; Ibach B
    Pharmacopsychiatry; 2010 Mar; 43(2):73-80. PubMed ID: 20131207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets.
    Chue P; Eerdekens M; Augustyns I; Lachaux B; Molcan P; Eriksson L; Pretorius H; David AS
    Eur Neuropsychopharmacol; 2005 Jan; 15(1):111-7. PubMed ID: 15572280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind trial of risperidone vs. quetiapine.
    Nakonezny PA; Byerly MJ; Rush AJ
    J Sex Marital Ther; 2007; 33(3):203-16. PubMed ID: 17454518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.